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Abstract
Patients in Colombia affected by cutaneous leishmaniasis (CL) face significant geopolitical and
socioeconomic barriers to accessing diagnosis and treatment. This study aimed to understand
how the geosocial characteristics of a patient’s area of residence affect time to medical
consultation and disease status at consultation. An observational cross-sectional study was
performed of individuals with CL who consulted at a local clinical referral center (CIDEIM) in
Cali and Tumaco, Colombia. Descriptive, bivariate, and multivariable simple and ordinal logistic
regression analyses were done to examine how area of residence (urban or rural) and cost of
transportation to the nearest urban center may influence complexity and time of evolution of the
disease at first medical visit. Two separate disease complexity classifications – cplexA and
cplexB - were created based on factors such as mucosal involvement, lymphatic dissemination,
and varying number and size of lesions; a composite score of both definitions was also
constructed. CL Patients who had to pay greater than $60,000 COP for transportation were more
likely to have a complex disease state at consultation based on the cplexA criteria (aOR = 2.11
[95% CI: 1.11 – 4.02]) and had higher odds of presenting with more complex disease (ordinal
logistic regression; aOR = 1.78 [95% CI: 1.09 – 2.92]). A protective association between rurality
and the time of evolution for the first lesion was also seen, showing that patients who lived in
rural regions were less likely to have longer wait times before consulting at CIDEIM when
compared to those who lived in urban centers (aOR = 0.66 [95% CI: 0.45 – 0.97]). High cost of
transportation to nearby urban centers remains a significant barrier to equitable access of medical
services for CL patients living in rural Colombia. Additionally, patients with CL in living nonendemic areas suffer extended time of evolution of the disease before consulting at a local
referral center, signifying a need for heighted clinical suspicion and services in urban areas.
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Introduction
Leishmaniasis is a neglected parasitic disease with a worldwide distribution, mainly affecting the
impoverished and most marginalized. The global incidence for cutaneous leishmaniasis (CL) is
estimated at 0.7 to 1.2 million new cases per year (1). CL is endemic in 98 countries worldwide,
of which Colombia is in the top ten countries with the highest incidence. It is estimated that more
than 11 million people are at risk for CL in Colombia, with the highest number of cases (52% of
total cases in 2017) centered in five departments: Antioquia, Santander, Nariño, Tolima and
Norte de Santander (2). Despite the fact that 77.7% of cutaneous leishmaniasis cases were
reported in rural areas, the majority of the studies analyzing risk factors focus on biological and
clinical correlates, often ignoring socioeconomic factors that promote a high disease burden in
these areas.

CL patients in rural Colombia face significant geographical, political and economic barriers to
securing high-quality diagnosis and treatment, often due to high income inequality and the threat
of violence from armed conflict (1,3,4). Access to care is a prevailing health issue in terms of
rural health, especially in developing countries (5,6). Previous research recognizes distance and
available transportation as barriers to accessing high-quality health services but other studies
have provided contradictory findings on how distance from healthcare access affects disease
prevention and treatment (5–8). Increased distance from health centers has shown to be
associated with increased delay from onset of symptom to diagnosis (9–11). Diagnostic delay has
also been shown to be associated with increased complexity of infectious disease pathogenesis,
providing a potential mechanism through which increased distance from a health center can act
as a barrier to health (12–15). These findings, however, while spanning both rural and urban
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regions, focus mostly on healthcare utilization in a general disease context, making the results
difficult to extrapolate to CL in Colombia, for which there is a clear dearth of research into the
social drivers of the disease.

Few studies have looked at how rurality and transportation affect patterns of healthcare access
for these patients in Colombia, or even in Latin America more broadly (16–19). A mixedmethods study on CL and gender in the country found that, due to the low fatality of the disease,
individuals living in remote, rural regions feel unmotivated to seek medical care unless the
disease rapidly progresses (11). Individuals with CL living in remote regions also seem to first
try home herbal remedies or antibiotic creams acquired from a local pharmacy before even
considering consulting at a clinic (3,11). One major shortcoming of the literature, however, is
that previous studies focus solely on time of evolution of this disease in either rural or urban
communities independently but have not sought to evaluate how an individual’s area of
residence is associated with time of evolution or complexity of disease at consultation.
Additionally, previous studies have used rurality solely as binary – rural or non-rural – but have
yet to further explore if their findings are consistent regardless of how far an individual in a rural
area lives from an urban center.

The current study evaluates how the area of residence – urban or rural - and cost of
transportation, a proxy for distance, from the patient’s community to the nearest urban center
may act as a barrier to health, potentially influencing time from onset of symptoms to
consultation at a local referral diagnostic center and complexity of disease, with the hope of
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elucidating the social factors that limit the access to diagnosis and treatment of CL in southwest
Colombia.

Methods:
Study Design and Area
This cross-sectional study was conducted by drawing from a database of clinical records of
patients diagnosed with CL between January 2012 and April of 2018 at the clinical referral
centers of the Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM) in
Tumaco and Cali (20).

Study Sample
Patients who met the following eligibility criteria were included: male and female individuals of
any age with a confirmed diagnosis of cutaneous leishmaniasis and a date of initial consultation
during the study period. Patients with an incomplete clinical history particularly regarding
confirmed Leishmania diagnosis or lesion characteristics were excluded.

Outcome Variables:
Complexity of Disease at Diagnosis

We are interested in cost of transportation and rurality as potential barriers that may lead to
diagnostic delay and more complex disease presentation at consultation. To capture disease
complexity, we created two variables based on factors such as mucosal involvement, lymphatic
dissemination, and varying number and size of lesions. For the cplexA, the following criteria had
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to be satisfied to classify the case as mild: no greater than one lesion, no lesion greater than three
centimeters in diameter, no evidence of lymphatic dissemination, and no evidence of mucocutaneous lesions. For cplexB, we classified an individual’s disease as mild if it met the
following criteria: no greater than four cutaneous lesions, no lesion greater than 5 cm in
diameter, no evidence of lymphatic dissemination, and no evidence of muco-cutaneous lesions.
If the above-mentioned criteria were not met, the individual was classified as having more
complex disease. These two variables are loosely informed by, but not adherent to, the treatment
guidelines issued by the World Health Organization (WHO) and the Pan-American Health
Organization (PAHO), by including those criteria related to disease complexity and excluding
those that were related to viability and safety of local treatment. Both the presence of
mucocutaneous lesions and evidence of lymphatic dissemination were added as they are
characteristic of more complex CL in the Americas (23). Given that the criteria for cplexB
presents a more conservative definition of complexity in which an individual cannot be classified
as more complex without first also being designated as more complex under the cplexA criteria,
we also created a three-level complexity variable as follows: mild, more complex only under
cplexA, more complex by both cplexA and cplexB criteria.

Time of Evolution

An extended time of evolution has been demonstrated to have a positive correlation with a more
complex pathology of visceral and cutaneous leishmaniasis globally (24). Time of evolution was
defined as the time from patient-reported symptom onset until consultation at CIDEM. Given
that the times of evolution are concentrated on the lower time scale (more than 50% report less a
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time of evolution less than 2 months) and that our primary objective was to understand barriers
to health access and not evaluate the natural history of the disease, time was operationalized into
a four-level variable: less than 1 month, between one and up to two months, between two and
three months, and greater than three months since the onset of symptoms.

Primary Independent Variables:
Area of Residence:
The area of residence of each patient was categorized as either urban or rural based on selfreport.

Distance and Cost:
Given that a significant portion of the patient population resides in rural areas and that the
geographical information regarding the veredas (a territorial subdivision focused primarily in
rural areas ) in Colombia is limited, estimates of distance through GIS information or straightline Euclidean distances are unavailable. In their place, we used the estimated cost of
transportation from every vereda to the urban center where each patient received their initial
diagnosis of CL under the assumption that higher costs of transport are associated with a greater
distance or travel time. Additionally, given that variety of transportation methods, including
water- and land-based transport, used to get from rural to urban areas, cost of transportation may
more accurately capture the true financial burden of seeking timely care as compared to a
straight-line estimation. For patients’ cost of transportation, we used values recently calculated
by Berger et al (25), which were based on local health care providers’ knowledge of
transportation options and costs. Given the monetary denominations of Colombia, the cost of
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transportation was then operationalized into a three-level variable: less than 20,000 COP,
between 20,000 and 60,000 COP, and greater than 60,000 COP.

Sociodemographic and Clinical Factors

Given that the immune response is dependent on or can be influenced by various
sociodemographic and clinical factors (11,26), age, sex, race, insurance type, occupation, history
of previous cutaneous lesions, presence of comorbidities, and parasite species were analyzed as
covariates.

Statistical analysis

We used simple descriptive statistics to describe the sociodemographic and clinical
characteristics of the sample. We then examined the bivariate associations between each of our
two primary independent variables of interest (urban/rural area of residence and cost of
transportation) and each of the outcomes of interest (cplexA, cplexB, the composite measure of
complexity, and time of evolution) using χ2 tests. For each of the two dichotomous outcomes
(cplexA and cplexB), we further used logistic regression analysis to quantify the unadjusted and
adjusted associations with both area of residence and transportation cost. For the two ordinal
outcomes (the 3-level composite measure of complexity and the 4-level time of evolution
variable), ordered logistic regression analysis was performed. To control for potential
confounders, each multivariable model included all sociodemographic and clinical variables that
were associated with the respective outcome variable at the 0.20 alpha level. All analyses were
conducted using SAS 9.4.
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Results:
Among the 982 individuals that consulted at CIDEIM between January 2012 and April 2018 and
had a laboratory-confirmed diagnosis of cutaneous leishmaniasis, 710 individuals had
information on their area of residence (urban versus rural), and 315 individuals had enough
detailed information regarding their address and vereda to estimate cost of transportation to their
CIDEIM referral center (25). The sociodemographic and clinical characteristics of each analytic
sample are presented in Table 1.

Table 1: Sample Characteristics
All patients with a positive
confirmed laboratory
diagnosis of CL (N = 982) *

Patients with complete
information about region
of residence (N = 710) *

Patients with complete
neighborhood and cost of
transportation data (N = 315) *

Characteristic
Age in years (in
years)
Male

n (%) or mean (SD)

n (%) or mean (SD)

n (%) or mean (SD)

30.7 (16.4)

30.4 (16.4)

28.3 (15.9)

753 (76.7)

549 (77.3)

244 (77.5)

Afrodecendent

456 (46.4)

313 (44.1)

121 (38.4)

Public Insurance

692 (70.5)

520 (73.2)

220 (69.8)

Work in Agriculture
Presence of
Comorbidities
History of Previous
Lesion
L.V. panamensis †

495 (50.4)

391 (55.1)

184 (58.4)

262 (26.7)

168 (23.7)

57 (18.1)

83 (8.5)

50 (7.1)

19 (6.0)

211/253(83.6)

125/156 (80.1)

71/82 (86.6)

576 (58.7)

576 (81.1)

223 (70.8)

Live in Rural Area

* Numbers may not sum to total due to missing data
† (n/N) - given that species identification is resource-intensive, it is only available for the patients that participated in
clinical trials and thus a high percentage of the sample has missing species data

The individuals with information regarding their area of residence were similar to the overall
patient population. They had an average age of 30.4 years. Five hundred forty-nine were male
(77.3%) and 44.1% identified as Afro-descendant. The majority of individuals worked in
agriculture (55.1%), lived in a rural area (81.1%), had public insurance (73.2), and were infected
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with Leishmania (Viannia) panemensis (80.1% out of those that had undergone species
identification). Additionally, 7.1% reported a history of previous skin lesions and 23.7`% had a
clinical comorbidity.

Patients for whom we had estimates of transportation costs had a mean age of 28.3 years and
were majority male (77.5%), had public insurance (69.8%), lived in a rural area (70.8%) and
were infected with L. panamensis (86.6% out of those that had undergone species identification).
One hundred twenty-one individuals identified as afro-descendent (38.4%), 58.4% worked in
agriculture, 6.0% reported a history of previous skin lesions and 18.1% had a clinical
comorbidity.

Unadjusted and adjusted associations of both area of residence and cost of transportation with
complexity of disease based on cplexA criteria are shown in Table 2. Overall, 74.6% of patients
were categorized as having more complex disease at initial consultation based on this definition.
Having to pay more than $60,000 COP for transportation from a patient’s vereda of residence to
the nearest urban center was associated with a significantly higher odds of being classified as
more complex compared with those who had to pay less than $20,000 COP (unadjusted OR =
1.91 [95% CI: 1.04 – 3.49]). The significant association persisted even after adjusting for
potential cofounders (adjusted OR = 2.11 [95% CI: 1.11 – 4.02]. Rural residence was associated
with lower odds of more complex disease at diagnosis; however, the association was not
statistically significant at the 0.05 level but it was marginally significant at the 0.1 level (p =
0.080).
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Table 2: Association of Area of Residence and Cost of Transportation with Disease Complexity based cplexA
Criteria
n (%) with more complex
Unadjusted OR
Adjusted* OR
N cutaneous leishmaniasis based on
(95%)
(95%)
cplexA criteria
Area of Residence (N = 700)
Urban

130

101 (77.7)

REF

REF

Rural
Cost of Transportation in
Colombian Pesos (N = 314)
< 20,000

570

398 (69.8)

0.67 (0.42, 1.04) 0.65 (0.40, 1.05)

155

105 (67.7)

REF

20,000 - 60,000

64

40 (62.5)

0.79 (0.43, 1.46) 0.89 (0.46, 1.71)

REF

>60,000
95
76 (80.0)
1.91 (1.04, 3.49) 2.11 (1.11, 4.02)
* Adjusted for race, sex, presence of comorbidities, and history of a previous lesion for Area of Residence model
(N = 664); Adjusted for age, sex, and the presence of comorbidities for Cost of Transportation model (N = 301)

As shown in Table 3, 35.9% of patients were categorized as more complex at initial consultation
using the cplexB criteria. Patients with transportation costs of less than $20,000 COP were the
least likely to be diagnosed with more complex disease; however, the association between
greater costs and cplexB-defined disease complexity did not reach statistical significance, nor did
the association between rural residence and lower odds of more complex disease.

Table 3: Association of Area of Residence and Cost of Transportation with Disease Complexity based on cplexB
Criteria
n (%) with more complex cutaneous
Unadjusted OR
Adjusted* OR
N
leishmaniasis based on cplexB criteria
(95%)
(95%)
Area of Residence (N = 694)
Urban

129

53 (41.1)

REF

REF

Rural
Cost of Transportation in
Colombian Pesos (N = 309)
< 20,000

565

192 (34.0)

0.74 (0.50, 1.09) 0.75 (0.50, 1.14)

152

37 (24.3)

REF

20,000 - 60,000

63

20 (31.8)

1.45 (0.76, 2.76) 1.44 (0.77, 2.70)

>60,000

94

28 (29.8)

1.32 (0.74, 2.35) 1.52 (0.76, 3.01)

REF

* Adjusted for race and the presence of comorbidities for Area of Residence model (N = 661); Adjusted for age,
sex, and insurance for Cost of Transportation model (N = 281)
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Crude analyses showed that individuals with a rural residence and those with transportation costs
less than $20,000 COP were the least likely to be diagnosed with more complex disease but the
association was not significant at the 0.05 level (Table 4). After adjusting for covariates,
however, individuals who had to pay an estimated cost of transportation greater than $60,000
COP were found to have a significantly higher odds of having more complex disease than those
individuals who have to pay less (adjusted OR = 1.78 [95% CI: 1.09 – 2.92]).

Table 4: Association of Area of Residence and Cost of Transportation with Composite Complexity Score
n (%) who had n (%) who had n (%) who had
Unadjusted OR
Adjusted* OR
N
a low
a moderate
a higher
(95%)
(95%)
complexity
complexity
complexity
Area of Residence
(N = 694)
Urban
129
29 (22.5)
47 (36.4)
53 (41.1)
REF
REF
Rural
565
Cost of
Transportation in
Colombian Pesos (N
= 308)
< 20,000
152

172 (30.4)

201 (35.6)

192 (34.0)

0.71 (0.50, 1.01) 0.72 (0.50, 1.05)

50 (32.9)

65 (42.8)

37 (24.3)

REF

20,000 - 60,000

63

24 (38.1)

19 (30.2)

20 (31.6)

1.04 (0.60, 1.79) 1.22 (0.69, 2.15)

>60,000

93

19 (20.2)

47 (50.0)

28 (29.8)

1.54 (0.95, 2.49) 1.78 (1.09, 2.92)

REF

* Ordinal logistic regression; Adjusted for sex, race, and the presence of comorbidities for Area of Residence
model (N = 661); Adjusted for sex and the presence of comorbidities for Cost of Transportation model (N = 297)

Table 5 shows the unadjusted and adjusted associations of both area of residence and cost of
transportation with time of evolution of the patient’s first lesion. Living in a rural area was found
to be associated with a 35% decreased likelihood of having a longer time of evolution when
compared with those who lived in urban areas (unadjusted OR = 0.65 [95% CI: 0.46– 0.92]), and
the protective effect persisted after controlling for potential confounders (adjusted OR = 0.66
[95% CI: 0.45 – 0.97]). Individuals who had to pay less than $20,000 COP for transportation
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were found to be the least likely to have a higher time of evolution, but the association did not
reach statistical significance.

Table 5: Association of Area of Residence and Cost of Transportation with Time of Evolution
n (%) who n (%) who n (%) who n (%) who
had a time had a time had a time had a time
of evolution of evolution of evolution of evolution
Unadjusted OR
N
of <1
from 1 - <2 from 2 – 3
of > 3
Adjusted* OR (95%)
(95%)
month for months for months for months for
their first
their first
their first
their first
lesion
lesion
lesion
lesion
Area of
Residence (N =
699)
Urban
134 15 (11.2)
33 (24.6)
44 (32.8)
42 (31.3) REF
REF
Rural
565
Cost of
Transportation
in Colombian
Pesos (N = 308)
< 20,000
152

20 (5.3)

239 (42.3)

183 (32.4)

113 (20.0) 0.65 (0.46, 0.92) 0.66 (0.45,

6 (4.0)

81 (53.3)

45 (29.6)

20 (13.2)

REF

20,000 - 60,000

63

2 (3.2)

27 (42.9)

19 (30.2)

15 (23.8)

1.63 (0.95, 2.82) 1.36 (0.73,

2.56)

>60,000

93

7 (7.5)

36 (38.7)

29 (31.2)

21 (22.6)

1.48 (0.91, 2.40) 1.38 (0.77,

2.50)

0.97)

REF

* Ordinal logistic regression; Adjusted for age, race, sex, work, insurance, and the presence of comorbidities for the Area
of Residence model (N = 645); Adjusted for age, sex, race, insurance, and the presence of comorbidities for the Cost of
Transportation model (N = 271)

Upon stratifying the results by the two cities where CIDEIM is present, Cali and Tumaco, the
aforementioned effects remained consistent – an apparent association between increased disease
complexity and higher cost of transportation and a protective association between rurality and
time of evolution), especially for Tumaco where the majority of the patients in our sample sought
medical consultation (data not shown).
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Discussion

Using data from a local clinical referral center (CIDEIM) in southwest Colombia, this study
found that there was a positive association between cost of transportation from a patient’s vereda
to the nearest urban center and an increased likelihood of more complex cutaneous leishmaniasis
at first clinical consultation. CL Patients who had to pay greater than $60,000 COP for
transportation were more likely to be classified as having more complex disease based on the
cplexA criteria and had higher odds of presenting with more complex disease. Contrary to our
expectation, however, a protective association between rurality and the time of evolution for the
first lesion was also seen, showing that patients who lived in rural regions were less likely to
have longer wait times before consulting at CIDEIM when compared to those who lived in urban
centers. While not statistically significant, a similar protective association between rurality and
complexity was seen, where patients living in a rural residence were less likely to be diagnosed
with more complex disease when compared to those with urban residence.

While previous studies have attempted to understand barriers to CL diagnosis in rural regions of
Latin America (11,17,27,28), to our knowledge, the current study is the first to examine how
distance from an urban center, here estimated through cost of transportation, is associated with
time of evolution and complexity of disease at first visit to a local CL referral clinic. We uncover
a threshold effect, in which we only see a significant association between cost of transportation
and complexity of disease when patients need to pay greater than $60,000 COP. Assuming that
high cost is associated with either farther distances away from the urban center or a more
expensive mode of transportation (i.e. marine vs land transport), our results highlight that
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transportation is still a significant barrier to equitable health access in individuals living in rural
Colombia.

Interestingly, while we see a significant association with cost of transportation and complexity
using the cplexA criteria, the association using cplexB guidelines did not reach statistical
significance. A consistent trend, however, is still seen throughout: patients with less than
$20,000 COP in transportation costs have the lowest odds of being diagnosed with more
complex disease. Given that cplexB gives a more conservative definition of complexity, the cases
identified using this criterion are implied to be of high complexity while the cplexA criteria
captures moderate disease as well. The observed difference in statistical significance might be
explained through this differential complexity classification: individuals with moderate disease,
(cplexA) might not be motivated to consult a referral clinic at the nearest urban center if their
cost of transportation exceeds $60,000 COP but individuals with more complex CL (cplexB)
would be more willing to seek diagnosis and treatment, regardless of the cost. Ordinal logistic
regression of the complexity score created as a composite of both criteria revealed that CL
patients that had transportation costs that exceeded $60,000 COP had higher odds of being more
complex at time of consultation, supporting the idea that mostly individuals with more complex
disease would be willing to seek diagnosis and treatment despite the high cost.

Despite the few numbers of articles on CL and time of evolution, the majority of the literature
mentions rurality and associated factors – low trust in medical institution, the use of alternative
or home remedies, lack of urgency due to the non-fatal nature of the disease, the need for
multiple, costly hospital visits for treatment – as strong contributors to the high time of evolution
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seen in Colombian CL patients (11,17,27,29). The current study presents a contradictory
perspective: compared to those patients living in urban centers, patients living in rural areas had
significantly lower odds of longer evolution times for their first lesion. Similarly, patients living
in a rural residence were also less likely to be diagnosed with more complex disease, although
the association did not reach statistical significance. Given that the majority of CL cases occur in
rural regions and that in Colombia the disease is often pejoratively associated with remote
guerilla militants, urban centers are viewed as non-endemic regions for CL. While endemic areas
bare a higher disease burden, the lack of health professionals trained in a particular disease
diagnostic or the lack of clinical suspicion in non-endemic regions has shown to be associated
with increased diagnostic delay (30–33). Thus, in Colombia, individuals in urban centers might
be susceptible to diagnostic delay and longer times of evolution due to lack of clinical suspicion
of the disease in non-endemic regions of the country.

While CL is primarily considered a rural disease as infection usually occurs through zoonotic
transmission from either canine or sylvatic reservoir hosts, rapid deforestation and urbanization
in Latin America is bringing many people into contact with zoonotic Leishmania hosts and with
Phlebotomus sand flies (the insect vector for CL) (34). In Colombia, both rapid urbanization and
forced human migration as a result of armed conflict and drug trafficking has promoted an
increase in CL cases in the country (4). As cities continue to expand into previously forested
regions, the country may see an increase in CL cases in urban centers. Given the results of this
study, local governments and health departments may need to expand clinical diagnostic capacity
in order to prevent significant diagnostic delays.
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Interestingly, despite longer time of evolution being associated with higher disease complexity
(15,35,36), the current study fails to find a significant association between area of residence and
CL complexity at time of consultation, regardless of the guidelines used to classify the disease as
complex. The potential reasons – both clinical and social – are many, given the multiple risk
factors that may influence disease progression (15,26,28). Given that the outcome of CL is
highly dependent on the host’s immune system (23,37), however, one potential explanation
might be higher prevalence of malnutrition, which has been shown to suppress the immune
system and promote lesion persistence (38–41), in patients living in rural areas compared to
those living in urban centers (42,43). Malnutrition might be modifying the association between
area of residence and complexity but careful additional investigation is needed.

This study had the following limitations. Due to the lack of geographical information and clear
political definitions of veredas, neither straight-line Euclidean distance nor distance of roads
traveled could be determined. Since neither distance travelled nor direct costing of transportation
is routinely collected from patients, we had to approximate distance from each vereda to the
nearest urban center using estimated travel costs found in Berger et al (25). While these estimates
fail to account for variability in transportation methods, differences in routes, and individual
variation, the approximate transportation costs were estimated by healthcare professionals using
local knowledge and experience and are thus considered to be highly informed on the basis of
preferred route, diversity of mode of transportation, and local variation in costs. In regards to the
outcome variables, currently, to our knowledge, there is no validated complexity score for
cutaneous leishmaniasis. In order to quantify complexity, however, we used the treatment
guidelines for local therapy set by PAHO and the WHO as a general starting point, with some
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notable distinctions. We only included those criteria related to disease complexity and excluding
those that were related to viability and safety of local treatment. For example, both the WHO and
PAHO count lesions on the face and joints as ineligible for local treatment. Given that this
consideration is due to the potential risk of complication from local therapies such as
thermotherapy and cryotherapy at these locations and not with complexity or chronicity, we
decided to exclude them from the criteria. A similar rationale was applied with the criterion for
availability for follow- up. Since the Leishmania species found in Colombia are also capable of
inducing mucocutaneous lesions as well as capable of disseminating through the lymphatic tract,
both presence of mucocutaneus lesions and lymphatic dissemination were included as part of the
complexity criteria. We created a complexity score by combining the two criteria as a substitute
for a validated score but confirmatory evaluations should be done if a validated scale is created.
Additionally, only 347 individuals in our sample had undergone testing for parasite species
identification due to the time-intensive methodology and high cost. Despite this limitation, we
found no significant association of complexity or time of evolution with parasite species, even
when accounting for the missing data as an additional category in the variable. In the individuals
that did have information regarding parasite species, we found that greater than eighty percent
were infected with L. panamensis, which matches with the observed species distribution found
throughout the country (2). In addition to cost of transportation, there exist many different factors
that might influence an individual’s willingness to seek medical attention and ease of transport,
including remoteness, different modes of transportation, lack of roads, violence, drug trafficking,
etc. Future studies should work to uncover and address the other equally important influences
that act as barriers to equitable health for patients in rural Colombia. This research is also an
observational cross-sectional study using routine clinical data not specifically collected for the
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purpose of this investigation, meaning that causality cannot be inferred. Additionally, the quality
of self-reported variables could not be verified.

While the current study examines cost of transportation as it relates to time of evolution and
complexity at first medical visit, transportation cost should also be examined in relation to
treatment access, delay, and adherence for CL patients in rural regions. The current standard of
care for CL is a twenty-day injection regimen with meglumine antimoniate that requires the
patients to visit a clinic daily. A recent study conducted by Berger et al. (25) estimated that the
mean cost-per-cure from a patient perspective was $443 USD due to transportation, food,
lodging, medical and child care, which represents a significant cost given the monthly minimum
wage of about $260 USD (44). Future studies should address how a higher cost of transportation
might affect a patient’s willingness to seek and remain on treatment with meglumine antimoniate
and potentially with miltefosine, an equally efficacious oral medication that has recently been
incorporated into the standard of care in Colombia after being shown to be a potential alternative
(45,46).

In conclusion, our analysis revealed that a high cost of transportation to an urban center is
associated with increased likelihood of higher disease complexity at the time of first consultation
at a local referral center for patients with CL in rural Colombia. Our findings further demonstrate
that CL patients living in urban regions often present a higher time of evolution for the disease
and more complex disease at consultation, setting the basis for future research into the potential
causes for this phenomenon and underscoring the need for higher clinical suspicion and
diagnostic capabilities in rapidly-urbanizing regions currently classified as non-endemic for CL.
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Our study highlights that transportation in rural regions still remains a significant barrier to
equitable health access for CL patients in Colombia and warrants further investigation into
interventions that might improve diagnostic and treatment services for these individuals and
communities.

References:

21

1.

Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis Worldwide
and Global Estimates of Its Incidence. PLoS ONE [Internet]. 2012 May 31 [cited 2019 Apr
8];7(5). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365071/

2.

Torres Rodriguez GE. INFORME DEL EVENTO LEISHMANIASIS, HASTA EL
PERIODO EPIDEMIOLÓGICO XI, COLOMBIA, 2017 [Internet]. Instituto Nacional de
Salud; 2017. Available from: http://simposiovirologia.ins.gov.co/lineas-deaccion/SubdireccionVigilancia/Informe%20de%20Evento%20Epidemiolgico/LEISHMANIASIS%20PE%20XI
%202017.pdf

3.

Medina-Morales DA, Machado-Duque ME, Machado-Alba JE. Epidemiology of Cutaneous
Leishmaniasis in a Colombian Municipality. Am J Trop Med Hyg. 2017 Nov 8;97(5):1503–
7.

4.

Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The Neglected Tropical
Diseases of Latin America and the Caribbean: A Review of Disease Burden and
Distribution and a Roadmap for Control and Elimination. PLoS Negl Trop Dis. 2008 Sep
24;2(9):e300.

5.

Arcury TA, Preisser JS, Gesler WM, Powers JM. Access to transportation and health care
utilization in a rural region. J Rural Health Off J Am Rural Health Assoc Natl Rural Health
Care Assoc. 2005;21(1):31–8.

22

6.

Zielinski A, Borgquist L, Halling A. Distance to hospital and socioeconomic status
influence secondary health care use. Scand J Prim Health Care. 2013 Jun;31(2):83–8.

7.

Billi JE, Pai C-W, Spahlinger DA. The effect of distance to primary care physician on
health care utilization and disease burden. Health Care Manage Rev. 2007 Mar;32(1):22–9.

8.

Kadobera D, Sartorius B, Masanja H, Mathew A, Waiswa P. The effect of distance to
formal health facility on childhood mortality in rural Tanzania, 2005–2007. Glob Health
Action [Internet]. 2012 Nov 9 [cited 2018 Feb 25];5. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495250/

9.

Basher A, Nath P, Nabi SG, Selim S, Rahman MF, Sutradhar SR, et al. A Study on Health
Seeking Behaviors of Patients of Post-Kala-Azar Dermal Leishmaniasis. BioMed Res Int.
2015;2015:314543.

10. Lankila T, Näyhä S, Rautio A, Rusanen J, Taanila A, Koiranen M. Is geographical distance
a barrier in the use of public primary health services among rural and urban young adults?
Experience from Northern Finland. Public Health. 2016 Feb;131:82–91.
11. Velez ID, Hendrickx E, Robledo SM, Agudelo S del P. Gender and cutaneous leishmaniasis
in Colombia. Cad Saúde Pública. 2001 Feb;17(1):171–80.
12. Demissie M, Lindtjorn B, Berhane Y. Patient and health service delay in the diagnosis of
pulmonary tuberculosis in Ethiopia. BMC Public Health. 2002 Sep 25;2:23.
13. Said K, Hella J, Mhalu G, Chiryankubi M, Masika E, Maroa T, et al. Diagnostic delay and
associated factors among patients with pulmonary tuberculosis in Dar es Salaam, Tanzania.

23

Infect Dis Poverty [Internet]. 2017 Mar 24 [cited 2018 Mar 1];6. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364704/
14. Lawn SD, Whetham J, Chiodini PL, Kanagalingam J, Watson J, Behrens RH, et al. New
world mucosal and cutaneous leishmaniasis: an emerging health problem among British
travellers. QJM Int J Med. 2004 Dec 1;97(12):781–8.
15. Machado-Coelho GLL, Caiaffa WT, Genaro O, Magalhães PA, Mayrink W. Risk factors
for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med
Hyg. 2005 Jan;99(1):55–61.
16. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006 Dec
1;22(12):552–7.
17. Weigel MM, Armijos RX. The traditional and conventional medical treatment of cutaneous
leishmaniasis in rural Ecuador. Rev Panam Salud Pública. 2001 Dec;10:395–404.
18. Salomón OD, Acardi SA, Liotta DJ, Fernández MS, Lestani E, López D, et al.
Epidemiological aspects of cutaneous leishmaniasis in the Iguazú falls area of Argentina.
Acta Trop. 2009 Jan 1;109(1):5–11.
19. Rawlins SC, Tiwari T, Chadee DD, Validum L, Alexander H, Nazeer R, et al. American
cutaneous leishmaniasis in Guyana, South America. Ann Trop Med Parasitol. 2001 Apr
1;95(3):245–51.

24

20. Blanco VM, Cossio A, Martinez JD, Saravia NG. Clinical and Epidemiologic Profile of
Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment. Am
J Trop Med Hyg. 2013 Aug 7;89(2):359–64.
21. WHO Expert Committee on the Control of the Leishmaniases, World Health Organization,
editors. Control of the leishmaniases: report of a meeting of the WHO Expert Committee on
the Control of Leishmaniases, Geneva, 22-26 March 2010. Geneva: World Health
Organization; 2010. 186 p. (WHO technical report series).
22. Pan American Health Organization. Leishmaniasis in the Americas. Treatment
Recommendations. 2018;60.
23. Burza S, Croft SL, Boelaert M. Leishmaniasis. The Lancet. 2018 Sep 15;392(10151):951–
70.
24. Medley GF, Hollingsworth TD, Olliaro PL, Adams ER. Health-seeking behaviour,
diagnostics and transmission dynamics in the control of visceral leishmaniasis in the Indian
subcontinent [Internet]. Nature. 2015 [cited 2018 Feb 28]. Available from:
https://www.nature.com/articles/nature16042
25. Berger BA, Cossio A, Saravia NG, Castro M del M, Prada S, Bartlett AH, et al. Costeffectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment
of pediatric cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Apr 6;11(4):e0005459.
26. Castro M del M, Cossio A, Velasco C, Osorio L. Risk factors for therapeutic failure to
meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis
in Colombia: A cohort study. PLoS Negl Trop Dis. 2017 Apr 5;11(4):e0005515.

25

27. Armijos R, Weigel M, Izurieta R, Racines J, Zurita C, Herrera W, et al. The epidemiology
of cutaneous leishmaniasis in subtropical Ecuador. Trop Med Int Health. 1997;2(2):140–
152.
28. Araujo AR de, Portela NC, Feitosa APS, Silva OA da, Ximenes RAA, Alves LC, et al.
RISK FACTORS ASSOCIATED WITH AMERICAN CUTANEOUS LEISHMANIASIS
IN AN ENDEMIC AREA OF BRAZIL. Rev Inst Med Trop São Paulo [Internet]. 2016
[cited 2019 Apr 10];58. Available from:
http://www.scielo.br/scielo.php?script=sci_abstract&pid=S003646652016005000267&lng=en&nrm=iso&tlng=en
29. Moreira R da CR, Rebêlo JMM, Gama MEA, Costa JML. Awareness of American
tegumentary leishmaniasis (ATL) and use of alternative therapies in an endemic area in the
Amazon Region in the State of Maranhão, Brazil. Cad Saúde Pública. 2002 Feb;18(1):187–
95.
30. Thomas C, Nambudiri VE. 429. Delayed Diagnosis of Leprosy in a Non-Endemic Area:
Lessons From a Retrospective Case Series. Open Forum Infect Dis. 2018 Nov
26;5(suppl_1):S162–3.
31. Brustoloni YM, Baldissera PM, Brustoloni FM. Difficulties in Diagnosis of Malaria in
Non-Endemic Areas: A Case Report of a Child in Brazil. Malar Control Elimin [Internet].
2015 [cited 2019 Mar 25];4(2). Available from: https://www.omicsonline.com/openaccess/difficulties-in-diagnosis-of-malaria-in-nonendemic-areas-a-case-report-ofa-child-inbrazil-1000132.php?aid=61510

26

32. Roure S, Valerio L, Pérez-Quílez O, Fernández-Rivas G, Martínez-Cuevas O, AlcántaraRomán A, et al. Epidemiological, clinical, diagnostic and economic features of an
immigrant population of chronic schistosomiasis sufferers with long-term residence in a
non-endemic country (North Metropolitan area of Barcelona, 2002-2016). PLOS ONE.
2017 Sep 27;12(9):e0185245.
33. Zoller T, Naucke TJ, May J, Hoffmeister B, Flick H, Williams CJ, et al. Malaria
transmission in non-endemic areas: case report, review of the literature and implications for
public health management. Malar J. 2009 Apr 20;8(1):71.
34. Gil JF, Nasser JR, Cajal SP, Juarez M, Acosta N, Cimino RO, et al. Urban transmission of
American cutaneous leishmaniasis in Argentina: spatial analysis study. Am J Trop Med
Hyg. 2010 Mar;82(3):433–40.
35. Marsden PD. Mucosal leishmaniasis due to Leishmania (Viannia) braziliensis L(V)b in
Três Braços, Bahia-Brazil. Rev Soc Bras Med Trop. 1994 Jun;27(2):93–101.
36. Passos VMA, Barreto SM, Romanha AJ, Krettli AU, Volpini ÂC, Gontijo CMF, et al.
Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: clinical,
laboratorial, therapeutic and prospective aspects. Rev Soc Bras Med Trop. 2001
Feb;34(1):5–12.
37. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet Lond
Engl. 2005 Nov 29;366(9496):1561–77.

27

38. Maciel BLL, Lacerda HG, Queiroz JW, Galvão J, Pontes NN, Dimenstein R, et al.
Association of nutritional status with the response to infection with Leishmania chagasi.
Am J Trop Med Hyg. 2008 Oct;79(4):591–8.
39. Weigel MM, Armijos RX, Zurita C, Racines J, Reddy A, Mosquera J. Nutritional Status
and Cutaneous Leishmaniasis in Rural Ecuadorian Children. J Trop Pediatr. 1995 Feb
1;41(1):22–8.
40. Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and
Consequence of Malnutrition. Trends Immunol. 2016 Jun;37(6):386–98.
41. Schaible UE, Kaufmann SHE. Malnutrition and Infection: Complex Mechanisms and
Global Impacts. PLoS Med [Internet]. 2007 May [cited 2019 Apr 10];4(5). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1858706/
42. C. Smith L, Ruel M, Ndiaye A. Why Is Child Malnutrition Lower in Urban Than in Rural
Areas? Evidence from 36 Developing Countries. World Dev. 2005 Aug 1;33:1285–305.
43. Parra DC, Iannotti L, Gomez LF, Pachón H, Haire-Joshu D, Sarmiento OL, et al. The
nutrition transition in Colombia over a decade: a novel household classification system of
anthropometric measures. Arch Public Health [Internet]. 2015 Feb 16 [cited 2019 Apr
10];73(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361151/
44. Colombia raises minimum wage by 7 percent for 2017. Reuters [Internet]. 2016 Dec 30
[cited 2019 Apr 10]; Available from: https://www.reuters.com/article/us-colombiaeconomy-idUSKBN14J1U4

28

45. Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I,
Garcerant D, et al. Noninferiority of miltefosine versus meglumine antimoniate for
cutaneous leishmaniasis in children. J Infect Dis. 2012 Feb 15;205(4):684–92.
46. Sunyoto T, Potet J, Boelaert M. Why miltefosine—a life-saving drug for leishmaniasis—is
unavailable to people who need it the most. BMJ Glob Health [Internet]. 2018 May 3 [cited
2019 Apr 10];3(3). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935166/

29

